VX-770 manufacturers and suppliers in india

VX-770

CAS:: 873054-44-5

MF:: C24H28N2O3

MW:: 392.49

Suppliers by country/region

Company Type

Properties

Melting point:: 212-215°C

Boiling point:: 550.4±50.0 °C(Predicted)

Density: 1.187

storage temp.: Refrigerator

solubility: DMSO (Slightly), Ethyl Acetate (Slightly), Methanol (Slightly)

pka: 11.08±0.23(Predicted)

form: Solid

color: White to Light Brown

InChI: InChI=1S/C24H28N2O3/c1-23(2,3)16-11-17(24(4,5)6)20(27)12-19(16)26-22(29)15-13-25-18-10-8-7-9-14(18)21(15)28/h7-13,27H,1-6H3,(H,25,28)(H,26,29)

InChIKey: PURKAOJPTOLRMP-UHFFFAOYSA-N

SMILES: N1C2=C(C=CC=C2)C(=O)C(C(NC2=CC(O)=C(C(C)(C)C)C=C2C(C)(C)C)=O)=C1

Safety Information

Symbol(GHS): GHS08,GHS07

Signal word: Warning

Hazard statements: H361-H319-H315-H335

Precautionary statements: P264-P280-P302+P352-P321-P332+P313-P362-P201-P202-P281-P308+P313-P405-P501-P264-P280-P305+P351+P338-P337+P313P

HS Code: 29333990

Use

In January 2012, the US FDA approved ivacaftor for the treatment of cystic fibrosis (CF) in patients who have the G551D mutation of the CF transmembrane regulator (CFTR) and are at least 6 years old. Ivacaftor (also known as VX-770) is a CFTR potentiator that increases the open probability of CFTR, thus increasing chloride secretion particularly in the 5% of CF patients with the G551D/F508 gating/ processing mutation. Ivacaftor was discovered by medicinal chemistry optimization of a lead scaffold identified through high-throughput screening of a 228,000 compound collection. In cultured bronchial epithelial cells from a CF patient with F508del, ivacaftor increased chloride secretion (EC50=81 nM). Preparation of ivacaftor is accomplished via a multistep synthesis oftwointermediates, 4-oxo-1,4-dihydroquinoline-3-carboxylic acid and 5-amino-di-tert-butylphenyl methyl carbonate, which are coupled using propane phosphonic acid anhydride (T3P) to afford the amide; deprotection of the phenol then provides ivacaftor.